On the recordSeptember 20, 2016
Unfortunately, it's not our first hearing on such matters. I mean, we are talking and dealing with Turing and Valeant and Mylan and Gilead, and seeing a really disturbing pattern where Congress provides a variety of mechanisms to invest in innovation and pharmaceutical companies so that we get the right public health treatments and medicines and that we also have innovations.
Source
congress.gov




